5440672025-04-012025-06-305440672025-04-012025-06-30in-capmkt:OtherExpenses1Member5440672025-04-012025-06-30in-capmkt:OtherExpenses2Member5440672025-04-012025-06-30in-capmkt:OtherExpenses3Member5440672025-04-012025-06-30in-capmkt:OtherExpenses4Member5440672025-04-012025-06-30in-capmkt:OtherExpenses5Member5440672025-04-012025-06-30in-capmkt:OtherExpenses6Member5440672025-04-012025-06-30in-capmkt:OtherExpenses7Member5440672025-04-012025-06-30in-capmkt:OtherExpenses8Member5440672025-04-012025-06-30in-capmkt:OtherExpenses9Member5440672025-04-012025-06-30in-capmkt:OtherExpenses10Member5440672025-04-012025-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

544067

INNOVACAP

NOTLISTED

INE0DUT01020

INNOVA CAPTAB LIMITED

Main Board

Equity

2025-04-01

2026-03-31

2025-08-07

2025-07-30

INR

Millions

Quarterly

First quarter

Single segment

Drugs and Pharmaceutical products

2025-08-07

15:30:00

2025-08-07

16:35:00

Not applicable

2025-04-01

2025-06-30

Unaudited

Consolidated

3515420000

44830000

3560250000

2294440000

50470000

-137530000

390900000

28600000

110450000

396150000

3133480000

426770000

62750000

53870000

116620000

310150000

40000

310190000

572250000

5.42

The above consolidated financial results of Innova Captab Limited and its subsidiaries Holding and its subsidiaries together referred to as the Group have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India Regulations 2015 as amended The results for the quarter ended 30 June 2025 are available on the Company website under investor information section and on the stock exchange website The above consolidated financial results have been reviewed and recommended by Audit Committee at its meeting held on 07 August 2025 The Board of Directors at their meeting held on 07 August 2025 have approved the above results and taken them on record The statutory auditors of the Company have expressed an unmodified review conclusion on the consolidated financial results for the quarter ended 30 June 2025 The Group comprise the following entities all of which have been incorporated in India Innova Captab Limited Holding Company Univentis Medicare Limited Subsidiary Company Sharon Bio Medicine Limited Subsidiary Company Univentis Foundation Subsidiary The Group has only one reportable segment ie Drugs and pharmaceutical products as per IndAS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per the listing agreement are not applicable to the group The figures of the last quarter ended 31 March 2025 as reported in these consolidated financial results, are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the relevent financial year Also the figures upto the end of the third quarter had only been reviewed and not subject to audit

Power and fuel

93950000

Stores and spares consumed

49370000

Repairs and maintenance

30640000

Packing charges

40380000

Lab consumables

12140000

Legal and professional fee

11970000

CSR expenditure

8330000

Rates, fees and taxes

13470000

Freight charges

18520000

Other expenses

117380000

The Company has only one reportable segment ie Drugs and pharmaceutical products as per IndAS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per the listing agreement are not applicable to the group

Remeasurement of defined benefit obligation

90000

50000

40000